New trial
Phase I Trial of CA-4948 (IRAK4/FLT3 Inhibitor) with FOLFOX and Bevacizumab in Metastatic Colorectal Cancer
- Trial ID
- NCT06696768 on ClinicalTrials.gov
- Cancer type
- Colorectal Cancer
- Published in
- New in Oncology - May 29, 2025
The NCI is evaluating the safety and optimal dosing of CA-4948—an investigational IRAK4 and FLT3 inhibitor—in combination with FOLFOX plus bevacizumab as a first-line treatment for metastatic colorectal cancer.
More in colorectal cancer
-
New trial · Oct 15, 2026 · NCT07750158
Phase 3 STELLAR-316 tests zanzalintinib with or without pembrolizumab for ctDNA-positive, scan-negative colorectal cancer -
New trial · Oct 15, 2026 · NCT07842965
Phase 1/1b CHAMP adds CCR5 blockade with leronlimab to surgery, hepatic arterial floxuridine, and systemic therapy for colorectal liver metastases -
New trial · Oct 15, 2026 · NCT07551596
Phase 2 COMBAT tests botensilimab plus balstilimab for ctDNA-positive molecular residual disease in MSS colorectal cancer -
New trial · Oct 8, 2026 · NCT07811193
Phase 2 VVD-133214 WRN helicase covalent inhibitor + pembrolizumab (PD-1 antibody) in MSI/dMMR CRC -
New trial · Oct 8, 2026 · NCT07808151
Phase 2 porustobart CTLA-4 antibody + pembrolizumab PD-1 antibody in resectable MSS colon cancer